Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/22/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Patrick Reichenberger MBA

Wrong Patrick Reichenberger MBA?

Vice President, Commercial Operat...

Raptor Pharmaceutical Corp
9 Commercial Blvd Suite 200
Novato , California 94949
United States

Company Description: Raptor Pharmaceuticals Corp. (Raptor) is a development-stage biotechnology company. The Company is focused on the development of new drugs. Raptor is developing...   more
Background

Employment History

Board Memberships and Affiliations

  • Board Member
    Non-Employee

Education

  • M.B.A.
    Pepperdine University
  • B.S. , Biology
    University of California , Los Angeles
27 Total References
Web References
Management Team | Raptor Pharmaceutical Corp.
www.raptorpharma.com, 29 Jan 2013 [cached]
Patrick Reichenberger
...
Patrick Reichenberger Vice President, Commercial Operations
Patrick Reichenberger joined Raptor as the Vice President, Commercial Operations. He has over 20 years of experience in biotech/pharma sales and marketing including orphan product development and commercialization. Prior to joining Raptor, Mr. Reichenberger served as Senior Director at XOMA LLC. In this role he led XOMA's commercial development department with particular emphasis on XOMA 052, an anti-IL-1 antibody for cardiovascular disease and Behcet's Uveitis, an orphan disease. Prior to XOMA, Mr. Reichenberger managed marketing, sales, reimbursement and distribution at Questcor Pharmaceuticals supporting the re-launch of H.P. Acthar® Gel for the treatment of infantile spasm, an ultra-orphan, pediatric disease. Prior to Questcor, he held positions of increasing responsibility at Genentech, Athena Neurosciences, a division of Elan, and Parke-Davis Pharmaceuticals. Patrick has an M.B.A. from Pepperdine University, where he graduated with Honors, and a B.S. in Biology from University of California, Los Angeles.
Effective September 1, 2011, Ms. Tsuchimoto ...
ir.raptorpharma.com, 9 Nov 2014 [cached]
Effective September 1, 2011, Ms. Tsuchimoto and Mr. Reichenberger both received 3% increases to their fiscal year 2011 base salaries, Mr. Daley received a 5.8% increase and Dr. Rioux received a 7.6% increase to equate their salaries to the 45th percentile for the comparative companies in the Radford survey grouping for companies with under 50 employees.  These raises were to match merit increases among companies in the Radford survey and to maintain the relative position in the Radford survey grouping for companies with under 50 employees.
...
Patrick Reichenberger VP, Commercial Operations
...
Fiscal Year 2012 Goal Achievements for Patrick Reichenberger, Our Vice President, Commercial Operations  Mr. Reichenberger had a minor role in the achievement of our corporate program goals but achieved significant individual goals. Corporate program goals account for 15% of Mr. Reichenberger's fiscal year 2012 annual incentive bonus, while individual goals account for 85%.  Mr. Reichenberger's annual incentive bonus (which target was up to 27.5% of his base salary) for fiscal year 2012 totaled $50,000 and was based upon achieving 100% of his corporate program goal of establishing a European headquarters and hiring a European General Manager of European commercial operations and on achieving 100% of the following individual goals (representing an achievement score percentage of 85%):  setting up a patient registry by August 2012; establishing a reimbursement HUB for RP103 (RaptorCares™) by August 2012; commencing implementation of early-access, named patient program for cystinosis patients; continuing development of strategic financial model by major product programs in accordance with project plan; completing a European distribution agreement.
...
Patrick Reichenberger, VP, Commercial Operations
...
 On September 22, 2011, after a discussion of the equity compensation situation and alternatives, our board approved the recommendation of our Compensation Committee.  With respect to our Named Executive Officers and our non-employee directors, our board awarded stock options relating to fiscal year 2012 to purchase up to the following number of shares at an exercise price of $5.13 per share, vesting 6/48ths on the 6 month anniversary of the grant date and 1/48th per month thereafter, with a 10 year expiry from grant date: Dr. Starr 345,048 shares; Ms. Tsuchimoto, Mr. Daley and Dr. Rioux 113,616 shares each; and Mr. Reichenberger 90,000 shares.
...
In addition, our Named Executive Officers were awarded annual stock option grants to purchase up to the following number of shares: Dr. Starr 115,016 shares; Ms. Tsuchimoto, Mr. Daley and Dr. Rioux 37,872 shares each; and Mr. Reichenberger 20,000 shares.  Dr.
...
Patrick Reichenberger, VP, Commercial Operations
Patrick ...
ir.raptorpharma.com, 29 Jan 2013 [cached]
Patrick Reichenberger Vice President, Commercial Operations
Our success is dependent in part ...
ir.raptorpharma.com, 14 Nov 2011 [cached]
Our success is dependent in part upon the availability of our senior executive officers, including our Chief Executive Officer, Dr. Christopher M. Starr, our Chief Scientific Officer, Dr. Todd C. Zankel, our Chief Financial Officer, Kim R. Tsuchimoto, Ted Daley, the President of our clinical development subsidiary, Dr. Patrice P. Rioux, Chief Medical Officer of our clinical development subsidiary, Patrick Reichenberger, Vice President, Commercial Operations of our clinical development subsidiary and Kathlene Powell, Vice President, Quality Operations of our clinical development subsidiary.
Patrick ...
www.calbio2013.com, 13 Feb 2014 [cached]
Patrick Reichenberger
...
Patrick Reichenberger
Vice President, Commercial Operations, Raptor Pharmaceuticals
...
Patrick Reichenberger Patrick has over 20 years of experience in biotech/pharma sales and marketing including orphan product development and commercialization. He is responsible for global marketing and sales at Raptor Pharmaceuticals. Prior to joining Raptor, he served as Senior Director at XOMA LLC where he led XOMA's commercial development department. Patrick also managed marketing, sales, reimbursement and distribution at Questcor Pharmaceuticals supporting the re-launch of H.P. Acthar® Gel for the treatment of infantile spasm, an ultra-orphan, pediatric disease. Prior to Questcor, he held positions of increasing responsibility at Genentech, Athena Neurosciences, a division of Elan, and Parke-Davis Pharmaceuticals. Patrick has an M.B.A. from Pepperdine University, where he graduated with Honors, and a B.S. in Biology from University of California, Los Angeles.
Other People with the name "Reichenberger":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304